On March 26, 2019, the Louisiana Department of Health (LDH) and Department of Corrections (DOC) announced their selection of Asegua Therapeutics LLC (a subsidiary of Gilead Sciences, Inc.) as their hepatitis C subscription model pharmaceutical partner. A contract is set to be completed by June 1, 2019, with the official start of the subscription model and implementation of the state’s hepatitis C elimination plan anticipated on July 1, 2019. The contract will last five years. Asegua will provide the state with unrestricted access to its direct-acting antiviral medications. Financial details were not disclosed. Under the contract, Medicaid beneficiaries . . .